Adaptive Biotechnologies reported third quarter 2025 results, posting sales of US$93.97 million and net income of US$9.55 million, reversing a net loss from the same period last year, and raised its full-year revenue guidance for the MRD business to US$202–207 million.
This marked the company’s first profitable quarter while also posting nearly double the prior year’s sales for the period, reflecting meaningful operational momentum.
We’ll examine how Adaptive Biotechnologies’ return to profitability and raised revenue guidance could influence its investment narrative.
The latest GPUs need a type of rare earth metal called Dysprosium and there are only 36 companies in the world exploring or producing it. Find the list for free.
To own shares of Adaptive Biotechnologies, investors need to believe that the company’s rapid growth in its MRD (minimal residual disease) business, scale efficiencies, and improved reimbursement trends can support ongoing profitability and revenue expansion. The recent return to profitability and higher full-year MRD revenue guidance enhance confidence in near-term execution but do not entirely resolve the longer-term risk of sustained unprofitability, especially if gains prove temporary or are offset by challenges in other business areas.
Among the company’s recent updates, the November 2025 raised guidance for MRD revenue directly relates to the current momentum and is an important data point for those focused on revenue-driven catalysts. This optimism follows significant improvements in clinical volume and pricing, reflecting the integration of clonoSEQ into electronic medical records and consistent contract wins, key factors driving top-line performance and supporting the positive shift in quarterly earnings.
However, despite recent profitability, investors should also be aware that continued company-wide losses and cash burn could…
Read the full narrative on Adaptive Biotechnologies (it’s free!)
Adaptive Biotechnologies is projected to reach $350.6 million in revenue and $49.8 million in earnings by 2028. This outlook assumes an annual revenue growth rate of 19.5% and an earnings increase of $171 million from the current earnings of -$121.2 million.
Uncover how Adaptive Biotechnologies’ forecasts yield a $17.14 fair value, a 10% upside to its current price.
ADPT Earnings & Revenue Growth as at Nov 2025
Two members of the Simply Wall St Community placed fair value estimates for Adaptive Biotechnologies between US$7.88 and US$17.14 per share. These diverse opinions contrast with recent progress in profitability, reminding you that future cash flow risks remain a focus for many market participants.
Explore 2 other fair value estimates on Adaptive Biotechnologies – why the stock might be worth 49% less than the current price!
Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.
The market won’t wait. These fast-moving stocks are hot now. Grab the list before they run:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ADPT.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com